This preliminary trial was conducted at the National Eye Institute (NEI), which is part of the US National Institute of Health (NIH). The trial, which examined the effect of CF101 in a preclinical animal model, demonstrated that the drug was able to significantly reduce ocular disease symptoms via a definitive immunological mechanism of action.
Pnina Fishman, CEO of Can-Fite, said: “The current standard of care for patients with uveitis is steroids and general immunosuppression therapy. The lack of specific drugs for the treatment of this condition creates a need for novel targeted therapies such as the products Can-Fite develops.”